When: Thursday 12th November 2020 12:30 - 13.30 BST
Describe the bodies involved in making health technologies available in the UK
Consider their role in patient access
Differentiate NICE, AWMSG and SMC as per their realm of responsibilities
Compare the processes and timelines from the three UK reimbursement bodies NICE, AWMSG and SMC
Identify differences and similarities between the processes involved for each body
Describe particularities required for submissions for each body
Who would benefit from registering to attend this webinar:
Market Access professionals seeking to learn about the differences in reimbursement across the UK and/or considering reimbursement options in the UK.
The job functions that will benefit most include:
• Heads of Market Access
• Managing Directors
• Country Managers
• Chief Executives
• Policy Advisors
• Medical Directors
• Commercial Directors
• Policy Officers/Executives
• Marketing Directors
Peter Rouse is an experienced health economist who joined MAP Biopharma in November 2019 as a Senior Consultant within the HEOR team. Peter has a background in health economic consulting, specialising in health economic modelling for early pricing of assets and HTA submissions, whilst also covering other areas of evidence generation and synthesis, including systematic literature reviews, (network) meta-analysis, preparation of global value dossier, HTA landscape analysis, local reimbursement dossier preparation, and outcomes research using patient-level data. Peter has experience leading successful HTA submissions across Europe, including NICE, SMC and AWMSG, with focus on orphan products and gene therapies for rare disease areas and oncology. Prior to consultancy, Peter worked at the National Clinical Guideline Centre (NCGC) hosted by the Royal College of Physicians, specialising in discrete event simulation modelling for service delivery guidelines, whilst also working on disease specific projects such as type 2 diabetes, palliative care and asthma diagnosis and management. Peter holds a BA in Economics and International Relations from the University of Keele and an MSc in Health Economics and Decision Modelling from the University of Sheffield.
Priscila holds a PhD in Neuroscience and Biochemistry from the University of Groningen, the Netherlands, where she studied new therapies for patients with phenylketonuria (PKU) and other inborn errors of metabolism. Having published more than 10 peer-reviewed papers and given speeches at medical conferences around the world, she is passionate about science communication. In the past five years, she has focussed on medical communications and advertising, strategically compiling and presenting clinical data in compelling e-detail aids, briefing documents, leave pieces, websites, objection handlers, to name a few, while following the ABPI code of practice. At MAP BioPharma, she conducts clinical research interviews and assessments and supports HTA submissions in the UK and worldwide. Her experience spans several disease areas, including rare diseases, rheumatology, neurology, gastroenterology and oncology.
Copyright © 2020. MAP BioPharma Limited. All rights reserved.
MAP BioPharma Limited
Upper Pendrill Court, Ermine Street North
Papworth Everard, Cambridge
Cambridgeshire, CB23 3UY
+44 (0) 1480 832360
MAP BioPharma Limited is a registered company in England and Wales. Company Registration Number 08209281
VAT Group Registration Number GB 292 8576 52